Scarica l'app Stockscreener
1.02
3.01%
0.0298
Dopo l'orario di chiusura:
1.01
-0.01
-0.98%
Precedente Chiudi:
$0.9902
Aprire:
$1
Volume 24 ore:
847.15K
Relative Volume:
1.23
Capitalizzazione di mercato:
$94.94M
Reddito:
-
Utile/perdita netta:
$-35.47M
Rapporto P/E:
-1.7895
EPS:
-0.57
Flusso di cassa netto:
$-124.27M
1 W Prestazione:
+28.97%
1M Prestazione:
+0.99%
6M Prestazione:
-41.71%
1 anno Prestazione:
-62.36%
Intervallo 1D:
$0.944
$1.03
Intervallo di 1 settimana:
$0.6574
$1.03
Portata 52W:
$0.4603
$4.44
Prokidney Corp Stock (PROK) Company Profile
Nome
Prokidney Corp
Settore
Industria
Telefono
336-999-7028
Indirizzo
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Confronta PROK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.02 | 94.94M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-30 | Iniziato | JP Morgan | Neutral |
| 2024-09-10 | Iniziato | Guggenheim | Buy |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-07-25 | Iniziato | BTIG Research | Buy |
| 2022-12-21 | Iniziato | Jefferies | Buy |
| 2022-11-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Iniziato | UBS | Buy |
| 2022-10-14 | Iniziato | Citigroup | Buy |
| 2022-09-23 | Iniziato | BofA Securities | Buy |
| 2022-09-02 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Prokidney Corp Borsa (PROK) Ultime notizie
Is ProKidney Corp (PROK) positioned for future growth? - Sete News
ProKidney Corp (NASDAQ:PROK)’s 12-Month Price Target Currently Stands At 6 - Marketing Sentinel
Major Investment Alert: Carso De-C Inmobiliaria Acquires ProKidney Shares! - TipRanks
ProKidney Corp [PROK] Records 50-Day SMA of $1.0283 - knoxdaily.com
The Psychology of ProKidney Corp Inc. (PROK) Price Performance: Understanding Market Sentiment - investchronicle.com
Analytical Overview: ProKidney Corp (PROK)’s Ratios Tell a Financial Story - DWinneX
The ProKidney Corp (PROK) had a good session last reading, didn’t it? - uspostnews.com
Major Investment Alert: ProKidney Stock Sees New Stakeholder! - TipRanks
Major Investment Alert: ProKidney Stock Acquisition! - TipRanks
Major Investment Alert: ProKidney Stock Sees Significant Purchase! - TipRanks
Greensboro’s Once Great Win Is Now A ProKidney Failure - The Rhino Times of Greensboro -
Major Investment Alert: ProKidney Stock Sees Big Buy-In! - TipRanks
Control empresarial de capitales purchases $628,847 in ProKidney shares - Investing.com
Control empresarial de capitales purchases $628,847 in ProKidney shares By Investing.com - Investing.com Canada
Sei Investments Co. Makes New $69,000 Investment in ProKidney Corp. (NASDAQ:PROK) - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
PROK stock touches 52-week low at $0.49 amid market challenges - Investing.com India
Institutional owners may take dramatic actions as ProKidney Corp.'s (NASDAQ:PROK) recent 32% drop adds to one-year losses - simplywall.st
Bank of New York Mellon Corp Has $388,000 Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) - Yahoo Finance
PROK stock touches 52-week low at $0.94 amid market challenges - Investing.com India
ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView
ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks
ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus.com
ProKidney reports larger loss in 2024 as production resumes - Winston-Salem Journal
PROKIDNEY CORP. SEC 10-K Report - TradingView
ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024 - The Business Journals
ProKidney reports FY24 EPS (62c), consensus (59c) - TipRanks
ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease - Nasdaq
ProKidney Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
FDA Fast-Tracks ProKidney's CKD Treatment: $358M War Chest Fuels Breakthrough Development - StockTitan
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
ProKidney (PROK) Expected to Announce Quarterly Earnings on Thursday - Defense World
ProKidney (NASDAQ:PROK) Stock Price Down 2.7%Here's What Happened - MarketBeat
ProKidney stock hits 52-week low at $1.34 amid market challenges - Investing.com Australia
ProKidney stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
Head to Head Review: ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK), - Yahoo
ProKidney Corp (NASDAQ: PROK) Has Great Upside Potential - Stocks Register
ProKidney Corp [PROK] Chief Regulatory Officer makes an insider sale of 16,412 shares worth 41,030. - Knox Daily
JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm - The Malaysian Reserve
2025 Will Be A Major Year For ProKidney’s Rilparencel In CKD Treatment (NASDAQ:PROK) - Seeking Alpha
US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St
ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals
ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal
Prokidney Corp Azioni (PROK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):